Editorial: Tools to identify organ rejection and immune quiescence for biological understanding and personalized medical care

Biomarkers in Medicine

Volumn 4, Issue 1, 2010, Pages 115-121

  Keown, Paul A ^a   McMaster, W Robert ^a   McManus, Bruce M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALLOGRAFT; EDITORIAL; GENETIC PREDISPOSITION; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; ORGAN TRANSPLANTATION; PERSONALIZED MEDICINE; ALLOTRANSPLANTATION; IMMUNOLOGY; METABOLISM;

BIOLOGICAL MARKERS; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; INDIVIDUALIZED MEDICINE; TRANSPLANTATION, HOMOLOGOUS;

EID: 77951678267     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.73     Document Type: Editorial

References (65)

1. Parasuraman R, Yee J, Karthikeyan V, del Busto R: Infectious complications in renal transplant recipients. Adv. Chronic Kidney Dis. 13(3), 280-294 (2006).
2. Yao G, Albon E, Adi Y et al.: A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children. Health Technol. Assess. 10(49), iii-iv, ix-xi, 1-157 (2006).
3. Winkelmayer W, Weinstein M, Mittleman M, Glynn R, Pliskin J: Health economic evaluations: the special case of end-stage renal disease treatment. Med. Decis. Making 22(5), 417-430 (2002).
4. Keown P: Improving quality of life-the new target for transplantation. Transplantation 72(Suppl. 12), S67-S74 (2001).
5. Rodrigo E, Arias M: A practical approach to immune monitoring in kidney transplantation. Minerva Urol. Nefrol. 59, 337-352 (2007).
6. Girlanda R, Mannon R, Kirk A: Diagnostic tools for monitoring kidney transplant recipients. Semin. Nephrol. 27(4), 462-478 (2007).
7. Furness P, Philpott C, Chorbadjian M et al.: Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation 76(6), 969-973 (2003).
8. Gough J, Rush D, Jeffery J et al.: Reproducibility of the Banff schema in reporting protocol biopsies of stable renal allografts. Nephrol. Dial. Transplant. 17(6), 1081-1084 (2002).
9. Veronese F, Manfro R, Roman F et al.: Reproducibility of the Banff classifcation in subclinical kidney transplant rejection. Clin. Transplant. 19(4), 518-521 (2005).
10. Choo S: The HLA system: genetics, immunology, clinical testing, and clinical implications. Yonsei Med. J. 48 (1), 11-23 (2007).
11. Cornell L, Smith R, Colvin R: Kidney transplantation: mechanisms of rejection and acceptance. Annu. Rev. Pathol. 3, 189-220 (2008).
12. Nickerson P: The impact of immune gene polymorphisms in kidney and liver transplantation. Clin. Lab. Med. 28(3), 455-468, vii (2008).
13. Girnita D, Webber S, Zeevi A: Clinical impact of cytokine and growth factor genetic polymorphisms in thoracic organ transplantation. Clin. Lab. Med. 28(3), 423-40, vi (2008).
14. Dmitrienko S, Hoar D, Balshaw R, Keown P: Immune response gene polymorphisms in renal transplant recipients. Transplantation 80(12), 1773-1782 (2005).
15. Thakkinstian A, Dmitrienko S, Gerbase Delima M et al.: Association between cytokine gene polymorphisms and outcomes in renal transplantation: a meta-ana lysis of individual patient data. Nephrol. Dial. Transplant. 23(9), 3017-3023 (2008).
16. Goldfarb-Rumyantzev A, Naiman N: Genetic prediction of renal transplant outcome. Curr. Opin. Nephrol. Hypertens. 17(6), 573-579 (2008).
17. Burckart G: Pharmacogenomics: the key to improved drug therapy in transplant patients. Clin. Lab. Med. 28(3), 411-422, vi (2008).
18. Azarpira N, Sagheb M, Geramizadeh B, Darai M: Vitamin D receptor genotypes and kidney allograft rejection. Mol. Biol. Rep. 36(8), 2387-9232 (2009).
19. Millán O, Urtasun N, Brunet M: Biomarkers of the immunomodulatory effect of immunosuppressive drugs in transplant recipients. Transplant. Rev. 23(2), 120-128 (2009).
20. - effector T cells. Int. Immunol. 20(3), 421-431 (2008).
21. + T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl. Int. 20(10), 845-855 (2007).
22. Wenner P, Di Padova F, Keown P: Detection and quantifcation of cyclosporine in body fuids using an interleukin-2 reporter-gene assay. J. Immunol. Methods 201(1), 125-135 (1997).
23. Terasaki P: Humoral theory of transplantation. Am. J. Transplant. 3(6), 665-673 (2003).
24. Cai J, Terasaki P: Humoral theory of transplantation: mechanism, prevention, and treatment. Hum. Immunol. 66(4), 334-342 (2005).
25. Clarke W, Silverman B, Zhang Z, Chan D, Klein A, Molmenti E: Characterization of renal allograft rejection by urinary proteomic ana lysis. Ann. Surg. 237(5), 660-664; discussion 664-665 (2003).
26. Schaub S, Rush D, Wilkins J et al.: Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 15(1), 219-227 (2004).
27. Schaub S, Wilkins J, Nickerson P: Proteomics and renal transplantation: searching for novel biomarkers and therapeutic targets. Contrib. Nephrol. 160, 65-75 (2008).
28. Schaub S, Wilkins J, Antonovici M et al.: Proteomic-based identifcation of cleaved urinary b2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am. J. Transplant. 5(4 Pt 1), 729-738 (2005).
29. Kurian S, Grigoryev Y, Head S, Campbell D, Mondala T, Salomon DR: Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers. Int. Immunopharmacol. 7(14), 1948-1960 (2007).
30. Lin D, Hollander Z, Ng R et al.: Whole blood genomic biomarkers of acute cardiac allograft rejection. J. Heart Lung Transplant. 28(9), 927-935 (2009).
31. Gunther OP, Balshaw RF, Scherer A et al.: Functional genomic ana lysis of peripheral blood during early acute renal allograft rejection. Transplantation 88(7), 942-951 (2009).
32. Hayden P, El-Meanawy A, Schelling J, Sedor J: DNA expression ana lysis: serial ana lysis of gene expression, microarrays and kidney disease. Curr. Opin. Nephrol. Hypertens. 12(4), 407-414 (2003).
33. Henger A, Schmid H, Kretzler M: Gene expression ana lysis of human renal biopsies: recent developments towards molecular diagnosis of kidney disease. Curr. Opin. Nephrol. Hypertens. 13(3), 313-318 (2004).
34. Kurian S, Grigoryev Y, Head S, Campbell D, Mondala T, Salomon D: Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers. Int. Immunopharmacol. 7, 1948-1960 (2007).
35. Irizarry R, Hobbs B, Collin F et al.: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
36. Smyth G, Michaud J, Scott H: Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21, 2067-2075 (2005).
37. Gentleman R, Carey V, Bates D et al.: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5(10), R80 (2004).
38. Sarwal M, Chua M, Kambham N et al.: Molecular heterogeneity in acute renal allograft rejection identifed by DNA microarray profling. N. Engl. J. Med. 349(2), 125-138 (2003). (Pubitemid 36818782)
39. Einecke G, Reeve J, Mengel M et al.: Expression of B cell and immunoglobulin transcripts is a feature of infammation in late allografts. Am. J. Transplant. 8(7), 1434-1443 (2008).
40. Famulski K, Broderick G, Einecke G et al.: Transcriptome ana lysis reveals heterogeneity in the injury response of kidney transplants. Am. J. Transplant. 7(11), 2483-2495 (2007).
41. Mueller T, Einecke G, Reeve J et al.: Microarray ana lysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am. J. Transplant. 7(12), 2712-2722 (2007).
42. Flechner SM, Kurian SM, Head SR et al.: Kidney transplant rejection and tissue injury by gene profling of biopsies and peripheral blood lymphocytes. Am. J. Transplant. 4(9), 1475-1489 (2004).
43. Deng M, Eisen H, Mehra M et al.: Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profling. Am. J. Transplant. 6(1), 150-160 (2006).
44. Bermúdez-Crespo J, López JL: A better understanding of molecular mechanisms underlying human disease. Proteomics Clin. Appl. 1(9), 983-1003 (2007).
45. Biemann K: Mass spectrometric determination of the amino acid sequence of peptides and proteins. Mass Spectrom. 6(1), 1-76 (1987).
46. Mirza S, Olivier M: Methods and approaches for the comprehensive characterization and quantifcation of cellular proteomes using mass spectrometry. Physiol. Genomics 33(1), 3-11 (2008).
47. Ong S-E, Mann M: Mass spectrometry-based proteomics turns quantitative. Nat. Chem. Biol. 1(5), 252-262 (2005).
48. Traum AZ, Schachter AD: Transplantation proteomics. Pediatr. Transplant. 9(6), 700-711 (2005).
49. Petricoin EF, Ardekani AM, Hitt BA et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002).
50. Becker S, Cazares LH, Watson P et al.: Surfaced-enhanced laser desorption/ionization time-of-fight (SELDI-TOF) differentiation of serum protein profles of BRCA-1 and sporadic breast cancer. Ann. Surg. Oncol. 11(10), 907-914 (2004).
51. Wong YF, Cheung TH, Lo KW et al.: Protein profling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett. 211(2), 227-234 (2004).
52. Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW: Pattern ana lysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 3(12), 2310-2316 (2003).
53. Schaub S, Wilkins JA, Nickerson P: Proteomics and renal transplantation: searching for novel biomarkers and therapeutic targets. Contrib. Nephrol. 160, 65-75 (2008).
54. McManus C, Rose M, Dunn M: Proteomics of transplant rejection. Transplant. Rev. 20, 195-207 (2006).
55. Schaub S, Wilkins JA, Antonovici M et al.: Proteomic-based identifcation of cleaved urinary b2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am. J. Transplant. 5(4 Pt 1), 729-738 (2005).
56. Le-Niculescu H, Kurian S, Yehyawi N et al.: Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol. Psychiatry 14, 156-174 (2008).
57. Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 1(11), 845-867 (2002).
58. Gilbert SO: Exploring the human plasma proteome. Proteomics 5(13), 3223-3225 (2005).
59. Shen Y, Kim J, Strittmatter EF et al.: Characterization of the human blood plasma proteome. Proteomics 5(15), 4034-4045 (2005). (Pubitemid 41502498)
60. Anderson NL, Polanski M, Pieper R et al.: The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell Proteomics 3(4), 311-326 (2004).
61. Auffray C, Chen Z, Hood L: Systems medicine: the future of medical genomics and healthcare. Genome Med. 1(1), 2 (2009).
62. Ng P, Murray S, Levy S, Venter J: An agenda for personalized medicine. Nature 461(7265), 724-726 (2009).
63. Goodsaid F, Frueh F: Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 7(5), 773-782 (2006).
64. Goodsaid F, Frueh F: Implementing the U.S. FDA guidance on pharmacogenomic data submissions. Environ. Mol. Mutagen 48(5), 354-358 (2007).
65. Hudson T: Personalized medicine: a transformative approach is needed. CMAJ 180(9), 911-913 (2009).